Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR2 | Q92731 | 1/20 | 0.55 |
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.50 |
| ▸ | CYP11B2 | P19099 | 2/20 | 0.44 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.44 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.42 |
| ▸ | HSD17B1 | P14061 | 2/20 | 0.42 |
| ▸ | HSD17B2 | P37059 | 2/20 | 0.42 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.41 |
| ▸ | DCLRE1B | Q9H816 | 1/20 | 0.41 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.40 |
| ▸ | ACHE | P22303 | 1/20 | 0.39 |
| ▸ | PGR | P06401 | 1/20 | 0.39 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12261275 | 0.91 | ESR2 (0.50) | ESR2TAAR1CYP11B2TNKS2PTPN1 | |
| SCHEMBL12384874 | 0.88 | ESR2 (0.36) | ESR2HSD17B1HSD17B2 | |
| SCHEMBL12261117 | 0.87 | MGLL (0.50) | ESR2TAAR1CYP11B2HSD17B1HSD17B2 | |
| SCHEMBL177425 | 0.86 | MGLL (0.48) | ESR2TAAR1CYP11B2HSD17B1HSD17B2 | |
| SCHEMBL29955002 | 0.86 | MGLL (0.48) | ESR2TAAR1CYP11B2HSD17B1HSD17B2 | |
| SCHEMBL12384885 | 0.86 | ESR2 (0.49) | ESR2TAAR1CYP11B2TNKS2PTPN1 | |
| SCHEMBL14753490 | 0.85 | ACHE (0.45) | ESR2HSD17B1HSD17B2PDK2ACHE | |
| SCHEMBL177530 | 0.84 | ESR2 (0.39) | ESR2TAAR1CYP11B2TNKS2HSD17B1 | |
| SCHEMBL257792 | 0.83 | ESR2 (0.53) | ESR2TAAR1CYP11B2TNKS2PTPN1 | |
| SCHEMBL257746 | 0.82 | ERN1 (0.42) | ESR2TNKS2ACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150344503-A1 | INHIBITORS OF FATTY ACID AMIDE HYDROLASE, METHODS OF TREATMENT AND METHODS OF PREPARING SAME | INFINITY PHARMACEUTICALS INC (US) | 2015-12-03 | — | — | US | claimed |
| US-20250120311-A1 | COMPOUND FOR ORGANIC OPTOELECTRONIC DEVICE, COMPOSITION FOR ORGANIC OPTOELECTRONIC DEVICE, ORGANIC OPTOELECTRONIC DEVICE, AND DISPLAY DEVICE | SAMSUNG SDI CO., LTD. (KR) | 2025-04-10 | — | — | US | disclosed |
| EP-4458822-A1 | COMPOUND FOR ORGANIC OPTOELECTRONIC DEVICE, COMPOSITION FOR ORGANIC OPTOELECTRONIC DEVICE, ORGANIC OPTOELECTRONIC DEVICE, AND DISPLAY DEVICE | Samsung SDI Co., Ltd. (KR) | 2024-11-06 | — | — | EP | disclosed |
| WO-2023128513-A1 | COMPOUND FOR ORGANIC OPTOELECTRONIC DEVICE, COMPOSITION FOR ORGANIC OPTOELECTRONIC DEVICE, ORGANIC OPTOELECTRONIC DEVICE, AND DISPLAY DEVICE | 삼성에스디아이 주식회사 | 2023-07-06 | — | — | WO | disclosed |
| US-20180244700-A1 | METHODS OF TREATING A FATTY ACID AMIDE HYDROLASE-MEDIATED CONDITION | INFINITY PHARMACEUTICALS, INC. | 2018-08-30 | — | — | US | disclosed |
| US-9951089-B2 | Methods of treating a fatty acid amide hydrolase-mediated condition | INFINITY PHARMACEUTICALS, INC. (US) | 2018-04-24 | — | — | US | disclosed |
| US-9951089-B2 | Methods of treating a fatty acid amide hydrolase-mediated condition | INFINITY PHARMACEUTICALS, INC. (US) | 2018-04-24 | — | — | US | disclosed |
| US-9951089-B2 | Methods of treating a fatty acid amide hydrolase-mediated condition | INFINITY PHARMACEUTICALS, INC. (US) | 2018-04-24 | — | — | US | disclosed |
| US-20150344503-A1 | INHIBITORS OF FATTY ACID AMIDE HYDROLASE, METHODS OF TREATMENT AND METHODS OF PREPARING SAME | INFINITY PHARMACEUTICALS INC (US) | 2015-12-03 | — | — | US | disclosed |
| US-20150344503-A1 | INHIBITORS OF FATTY ACID AMIDE HYDROLASE, METHODS OF TREATMENT AND METHODS OF PREPARING SAME | INFINITY PHARMACEUTICALS INC (US) | 2015-12-03 | — | — | US | disclosed |
| US-20110201574-A1 | FATTY ACID AMIDE HYDROLASE INHIBITORS | INFINITY PHARMACEUTICALS, INC. | 2011-08-18 | — | — | US | disclosed |
| US-20110201574-A1 | FATTY ACID AMIDE HYDROLASE INHIBITORS | INFINITY PHARMACEUTICALS, INC. | 2011-08-18 | — | — | US | disclosed |
| US-20110201574-A1 | FATTY ACID AMIDE HYDROLASE INHIBITORS | INFINITY PHARMACEUTICALS, INC. | 2011-08-18 | — | — | US | disclosed |
| WO-2011097233-A1 | FATTY ACID AMIDE HYDROLASE INHIBITORS | INFINITY PHARMACEUTICALS, INC. (US) | 2011-08-11 | — | — | WO | disclosed |
| WO-2011097233-A1 | FATTY ACID AMIDE HYDROLASE INHIBITORS | INFINITY PHARMACEUTICALS, INC. (US) | 2011-08-11 | — | — | WO | disclosed |
| US-7947663-B2 | Inhibitors of fatty acid amide hydrolase | INFINITY PHARMACEUTICALS, INC. (US) | 2011-05-24 | — | — | US | disclosed |
| US-7947663-B2 | Inhibitors of fatty acid amide hydrolase | INFINITY PHARMACEUTICALS, INC. (US) | 2011-05-24 | — | — | US | disclosed |
| US-20090099131-A1 | INHIBITORS OF FATTY ACID AMIDE HYDROLASE | INFINITY DISCOVERY, INC. (US) | 2009-04-16 | — | — | US | disclosed |
| US-20090099131-A1 | INHIBITORS OF FATTY ACID AMIDE HYDROLASE | INFINITY DISCOVERY, INC. (US) | 2009-04-16 | — | — | US | disclosed |
| WO-2008063300-A2 | BORONIC ACIDS AND ESTERS AS INHIBITORS OF FATTY ACID AMIDE HYDROLASE | INFINITY PHARMACEUTICALS, INC. (US) | 2008-05-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110201574-A1 | FATTY ACID AMIDE HYDROLASE INHIBITORS | FAAH, FAAH2, FASN | ESR2 3039/4885TAAR1 2103/4885CYP11B2 3327/4885 |
| US-20180244700-A1 | METHODS OF TREATING A FATTY ACID AMIDE HYDROLASE-MEDIATED CONDITION | FAAH, FAAH2, FASN | ESR2 2277/4885TAAR1 2133/4885CYP11B2 2852/4885 |
| US-20090099131-A1 | INHIBITORS OF FATTY ACID AMIDE HYDROLASE | FAAH, FAAH2, ASAH1 | ESR2 4177/4885TAAR1 616/4885CYP11B2 835/4885 |
| US-20150344503-A1 | INHIBITORS OF FATTY ACID AMIDE HYDROLASE, METHODS OF TREATMENT AND METHODS OF PREPARING SAME | FAAH, FAAH2, ASAH1 | ESR2 4255/4885TAAR1 745/4885CYP11B2 772/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.